Vertex Pharmaceuticals Incorporated VRTX today announced that
Health Canada has approved INCIVEK(TM) (telaprevir) tablets for a broad
group of people with genotype 1 chronic hepatitis C with compensated liver
disease (some level of damage to the liver but the liver still functions),
including cirrhosis (scarring of the liver). INCIVEK is
approved for use in combination with pegylated-interferon and ribavirin, two
other medicines approved to treat hepatitis C, and is indicated for people
who are new to treatment, and for people who were treated previously but who
did not achieve a sustained viral response (SVR, or viral cure). INCIVEK is
approved for use in all three major groups of people who did not achieve a
viral cure despite prior treatment including: relapsers, partial responders
and null responders.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in